Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)

Introduction: Immune checkpoint inhibitors (ICIs) are now standard of care in many cancers. They can generate immune-related adverse events (irAEs), but no biomarkers are available to identify patients who are more likely to develop irAEs. We assess the association between pre-existing autoantibodie...

Descripción completa

Detalles Bibliográficos
Autores principales: Daban, A, Gonnin, C, Phan, L, Saldmann, A, Granier, C, Lillo-Lelouet, A, Le Beller, C, Pouchot, J, Weiss, l, Tartour, E, Fabre, E, Medioni, J, Oudard, S, Vano, YA, Dragon-Durey, MA, Simonaggio, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177742/
https://www.ncbi.nlm.nih.gov/pubmed/37187974
http://dx.doi.org/10.1080/2162402X.2023.2204754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177742/
https://www.ncbi.nlm.nih.gov/pubmed/37187974
http://dx.doi.org/10.1080/2162402X.2023.2204754

Ejemplares similares